Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “mab”

86 pharma patents match "mab" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 86
Index total 30,257
Page 4 / 4

Quick answer

This filtered view shows 86 pharmaceutical patents matching "mab" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

86 results for “mab” · 30,257 patents in full index Clear search

  1. US 9724414

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted

  2. US 9724415

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted

  3. US 9707293

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jul 18, 2017 · Expires Jul 13, 2037

    granted

  4. US 9682145

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted

  5. US 9382317

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jul 5, 2016 · Expires Jun 30, 2036

    granted

  6. US 9346880

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted May 24, 2016 · Expires May 19, 2036

    granted

  7. US 9340611

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted May 17, 2016 · Expires May 12, 2036

    granted

  8. US 9340612

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted May 17, 2016 · Expires May 12, 2036

    granted

  9. US 8652443

    Foamable microemulsion compositions for topical administration

    Precision Dermatology, Inc. · Granted Feb 18, 2014 · Expires Feb 13, 2034

    granted

  10. US 8604184

    Chemically programmable immunity

    United States of America as represented by the Secretary of the Air Force · Granted Dec 10, 2013 · Expires Dec 5, 2033

    granted

  11. US 8029788

    Variants of humanized anti-carcinoma MAb CC49

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  12. US 7763719

    Variants of humanized anti-carcinoma MAb CC49

    The United States of America, as represented by the Department of Health and Human Services · Granted Jul 27, 2010 · Expires Jul 22, 2030

    granted

  13. US 7189396

    Delivery system using mAb 3E10 and mutants and/or functional fragments thereof

    The Regents of the University of California · Granted Mar 13, 2007 · Expires Mar 8, 2027

    granted

  14. US 6780413

    Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders

    The United States of America, as represented by the Department of Health and Human Services · Granted Aug 24, 2004 · Expires Aug 19, 2024

    expired

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.